Chetan B Patel1, Laura Blue1, Barbara Cagliostro2, Stephen H Bailey3, John W Entwistle4, Ranjit John5, Vinay Thohan6, Joseph C Cleveland7, Daniel J Goldstein8, Nir Uriel2, Xiaolu Su9, Sami I Somo9, Poornima Sood9, Mandeep R Mehra10. 1. Duke University Medical Center, Durham, North Carolina. 2. New York-Presbyterian/Columbia University Medical Center, New York, New York. 3. Allegheny General Hospital, Pittsburgh, Pennsylvania. 4. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. 5. University of Minnesota Medical Center, Minneapolis, Minnesota. 6. Mission Health System, Asheville, North Carolina. 7. University of Colorado School of Medicine, Aurora, Colorado. 8. Montefiore Einstein Center for Heart and Vascular Care, New York, New York. 9. Abbott, Abbott Park, Illinois. 10. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: mmehra@bwh.harvard.edu.
Abstract
BACKGROUND: In a randomized controlled trial (MOMENTUM 3), the HeartMate 3 (HM3) fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) demonstrated superiority over the HeartMate II (HMII) axial-flow LVAD. These findings were driven by hemocompatibility-related outcomes, but infection-related outcomes were not altered by device choice. In this trial-level analysis, we analyzed the clinical patterns of infection-related outcomes over 2 years of support. METHODS: In MOMENTUM 3, 1,020 patients were implanted with either the HM3 (n = 515) orHMII (n = 505) pump. Clinical characteristics and morbidity- and mortality-related outcomes were evaluated to identify predictors associated with major infectious complications, using univariable and multivariable models. RESULTS: The cumulative number of infections at 2 years was 1,213 (634 HM3 and 579 HMII), and major infection occurred in 58% of patients with the HM3 and 56% of patients with the HMII (p = 0.57). Infections of a local nature unrelated to pump components were most common (n = 681/1,213; 56%), followed by driveline-associated infection (n = 329/1,213; 27%), sepsis (n = 194/1,213; 16%), and other events (n = 9/1,213; 0.7%). Bacterial pathogens were implicated in 806 of 1,213 events (66%); significant predictors of infection included sex (women vs men; hazard ratio [HR]: 1.38, p = 0.003), pre-implant use of intra-aortic balloon pump (HR: 1.33, p = 0.02), pre-implant history of cardiac surgery (HR: 1.28, p = 0.01), and body mass index ≥ 30 (HR: 1.40, p < 0.0001). Most deaths in those with infection occurred owing to non-infectious causes. CONCLUSION: Infection is the most common adverse effect in patients implanted with contemporary continuous-flow LVADs, with most such events unrelated to the pump or its peripheral components. Whether chronic mechanical circulatory devices confer an immunomodulatory effect pre-disposing to infection warrants closer scrutiny to understand and ameliorate this morbidity.
RCT Entities:
BACKGROUND: In a randomized controlled trial (MOMENTUM 3), the HeartMate 3 (HM3) fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) demonstrated superiority over the HeartMate II (HMII) axial-flow LVAD. These findings were driven by hemocompatibility-related outcomes, but infection-related outcomes were not altered by device choice. In this trial-level analysis, we analyzed the clinical patterns of infection-related outcomes over 2 years of support. METHODS: In MOMENTUM 3, 1,020 patients were implanted with either the HM3 (n = 515) or HMII (n = 505) pump. Clinical characteristics and morbidity- and mortality-related outcomes were evaluated to identify predictors associated with major infectious complications, using univariable and multivariable models. RESULTS: The cumulative number of infections at 2 years was 1,213 (634 HM3 and 579 HMII), and major infection occurred in 58% of patients with the HM3 and 56% of patients with the HMII (p = 0.57). Infections of a local nature unrelated to pump components were most common (n = 681/1,213; 56%), followed by driveline-associated infection (n = 329/1,213; 27%), sepsis (n = 194/1,213; 16%), and other events (n = 9/1,213; 0.7%). Bacterial pathogens were implicated in 806 of 1,213 events (66%); significant predictors of infection included sex (women vs men; hazard ratio [HR]: 1.38, p = 0.003), pre-implant use of intra-aortic balloon pump (HR: 1.33, p = 0.02), pre-implant history of cardiac surgery (HR: 1.28, p = 0.01), and body mass index ≥ 30 (HR: 1.40, p < 0.0001). Most deaths in those with infection occurred owing to non-infectious causes. CONCLUSION:Infection is the most common adverse effect in patients implanted with contemporary continuous-flow LVADs, with most such events unrelated to the pump or its peripheral components. Whether chronic mechanical circulatory devices confer an immunomodulatory effect pre-disposing to infection warrants closer scrutiny to understand and ameliorate this morbidity.
Authors: K Dennie Kim; Russell J Funk; Hechuan Hou; Austin Airhart; Khalil Nassar; Francis D Pagani; Min Zhang; P Paul Chandanabhumma; Keith D Aaronson; Carol E Chenoweth; Ahmad Hider; Lourdes Cabrera; Donald S Likosky Journal: Circ Cardiovasc Qual Outcomes Date: 2022-09-06
Authors: Heidi S Lumish; Barbara Cagliostro; Lorenzo Braghieri; Bruno Bohn; Giulio M Mondellini; Karen Antler; Vivian Feldman; Audrey Kleet; Jennifer Murphy; Melie Tiburcio; Kathryn Fidlow; Douglas Jennings; Gabriel T Sayer; Koji Takeda; Yoshifumi Naka; Ryan T Demmer; Justin G Aaron; Nir Uriel; Paolo C Colombo; Melana Yuzefpolskaya Journal: ASAIO J Date: 2022-03-01 Impact factor: 3.826
Authors: Shiwei Zhou; Guangyu Yang; Min Zhang; Michael Pienta; Carol E Chenoweth; Francis D Pagani; Keith D Aaronson; Michael D Fetters; P Paul Chandanabhumma; Lourdes Cabrera; Hechuan Hou; Preeti N Malani; Donald S Likosky Journal: J Thorac Cardiovasc Surg Date: 2021-11-09 Impact factor: 6.439
Authors: Nelianne J Verkaik; Yunus C Yalcin; Hannelore I Bax; Alina A Constantinescu; Jasper J Brugts; Olivier C Manintveld; Ozcan Birim; Peter D Croughs; Ad J J C Bogers; Kadir Caliskan Journal: Front Med (Lausanne) Date: 2022-05-24
Authors: Florin Alexandru Pleșoianu; Carmen Elena Pleșoianu; Iris Bararu Bojan; Andrei Bojan; Andrei Țăruș; Grigore Tinică Journal: Bioengineering (Basel) Date: 2022-05-06
Authors: Melana Yuzefpolskaya; Heidi S Lumish; Azka Javaid; Barbara Cagliostro; Giulio M Mondellini; Bruno Bohn; Austin Sweat; Duygu Onat; Lorenzo Braghieri; Koji Takeda; Yoshifumi Naka; Gabriel T Sayer; Nir Uriel; Justin G Aaron; Emmanuel Montassier; Ryan T Demmer; Paolo C Colombo Journal: Eur J Heart Fail Date: 2021-05-31 Impact factor: 17.349
Authors: Tomasz Dziodzio; Mariusz Kuśmierczyk; Andrzej Juraszek; Mikołaj Smólski; Piotr Kołsut; Jarosław Szymański; Paweł Litwiński; Krzysztof Kuśmierski; Joanna Zakrzewska-Koperska; Maciej Sterliński Journal: J Cardiothorac Surg Date: 2021-08-03 Impact factor: 1.637
Authors: Jane E Wilcox; Rebecca S Harap; Valentina Stosor; Elaine R Cohen; Kathleen L Grady; Kenzie A Cameron; Denise M Scholtens; Diane B Wayne; Kerry B Shanklin; Gretchen P Nonog; Lauren E Schulze; Alison M Jirak; Grace C Magliola; Jeffrey H Barsuk Journal: J Cardiovasc Nurs Date: 2022 May-Jun 01 Impact factor: 2.468
Authors: Mandeep R Mehra; Joseph C Cleveland; Nir Uriel; Jennifer A Cowger; Shelley Hall; Douglas Horstmanshof; Yoshifumi Naka; Christopher T Salerno; Joyce Chuang; Christopher Williams; Daniel J Goldstein Journal: Eur J Heart Fail Date: 2021-05-18 Impact factor: 15.534